GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
GO:000640121 | Liver | HCC | RNA catabolic process | 201/7958 | 278/18723 | 3.88e-24 | 1.02e-21 | 201 |
GO:003465521 | Liver | HCC | nucleobase-containing compound catabolic process | 273/7958 | 407/18723 | 4.84e-24 | 1.23e-21 | 273 |
GO:190331121 | Liver | HCC | regulation of mRNA metabolic process | 205/7958 | 288/18723 | 3.38e-23 | 6.90e-21 | 205 |
GO:000640321 | Liver | HCC | RNA localization | 151/7958 | 201/18723 | 3.72e-21 | 5.89e-19 | 151 |
GO:000640221 | Liver | HCC | mRNA catabolic process | 169/7958 | 232/18723 | 4.50e-21 | 6.96e-19 | 169 |
GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
GO:005123621 | Liver | HCC | establishment of RNA localization | 121/7958 | 166/18723 | 1.61e-15 | 1.19e-13 | 121 |
GO:005065711 | Liver | HCC | nucleic acid transport | 118/7958 | 163/18723 | 8.30e-15 | 5.60e-13 | 118 |
GO:005065811 | Liver | HCC | RNA transport | 118/7958 | 163/18723 | 8.30e-15 | 5.60e-13 | 118 |
GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
GO:005102811 | Liver | HCC | mRNA transport | 97/7958 | 130/18723 | 9.00e-14 | 5.23e-12 | 97 |
GO:004348721 | Liver | HCC | regulation of RNA stability | 119/7958 | 170/18723 | 3.20e-13 | 1.71e-11 | 119 |
GO:004348821 | Liver | HCC | regulation of mRNA stability | 110/7958 | 158/18723 | 4.36e-12 | 1.93e-10 | 110 |
GO:006101321 | Liver | HCC | regulation of mRNA catabolic process | 114/7958 | 166/18723 | 7.38e-12 | 3.12e-10 | 114 |
GO:000989522 | Liver | HCC | negative regulation of catabolic process | 196/7958 | 320/18723 | 7.98e-12 | 3.35e-10 | 196 |
GO:003133022 | Liver | HCC | negative regulation of cellular catabolic process | 164/7958 | 262/18723 | 3.52e-11 | 1.35e-09 | 164 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGF2BP1 | SNV | Missense_Mutation | | c.718N>A | p.Ala240Thr | p.A240T | Q9NZI8 | protein_coding | tolerated(0.17) | benign(0.088) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGF2BP1 | SNV | Missense_Mutation | rs557111796 | c.500G>A | p.Arg167His | p.R167H | Q9NZI8 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
IGF2BP1 | insertion | In_Frame_Ins | novel | c.815_816insTTTGTGTCATAGGCTGTGTTCTTGTCCCCAACCACTGCTTGCTTATTT | p.Lys272delinsAsnLeuCysHisArgLeuCysSerCysProGlnProLeuLeuAlaTyrLeu | p.K272delinsNLCHRLCSCPQPLLAYL | Q9NZI8 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGF2BP1 | insertion | Frame_Shift_Ins | novel | c.1340_1341insACAGCATCCCTTGGCAGCCCAGGGTGGCGGTTTGG | p.Asp448GlnfsTer51 | p.D448Qfs*51 | Q9NZI8 | protein_coding | | | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
IGF2BP1 | insertion | Nonsense_Mutation | novel | c.1007_1008insCAGTGTGCTTCGTTTCATCAGAGACTAACCTGTGGGCAAAGTAA | p.Cys337SerfsTer9 | p.C337Sfs*9 | Q9NZI8 | protein_coding | | | TCGA-BH-A0HB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
IGF2BP1 | SNV | Missense_Mutation | | c.314N>C | p.Gly105Ala | p.G105A | Q9NZI8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IGF2BP1 | SNV | Missense_Mutation | | c.970G>A | p.Glu324Lys | p.E324K | Q9NZI8 | protein_coding | deleterious(0.03) | probably_damaging(0.951) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IGF2BP1 | SNV | Missense_Mutation | | c.1320N>C | p.Lys440Asn | p.K440N | Q9NZI8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
IGF2BP1 | SNV | Missense_Mutation | rs781338712 | c.1501C>T | p.Arg501Trp | p.R501W | Q9NZI8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
IGF2BP1 | SNV | Missense_Mutation | novel | c.1381N>A | p.Glu461Lys | p.E461K | Q9NZI8 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-VS-A9UP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |